Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05764720 · ClinicalTrials.gov registry record · NA
Stereotactic Adaptive Radiation Therapy of Borderline Resectable Pancreatic Cancer an Individualized Approach
A NA study of Pancreatic Cancer, sponsored by Varian, a Siemens Healthineers Company.
- Recruiting
- Registry status
- NA
- Development phase
- 134
- Enrollment target
- 3
- Study locations
NCT05764720: Recruiting NA study of Pancreatic Cancer, sponsored by Varian, a Siemens Healthineers Company.
NCT05764720 is a NA study of Pancreatic Cancer that is actively recruiting participants, run by Varian, a Siemens Healthineers Company. The registered enrollment target is 134 participants, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (66% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05764720, a NA study of Pancreatic Cancer, is actively recruiting participants, sponsored by Varian, a Siemens Healthineers Company.
- RECRUITING
- Registry status
- NA
- Development phase
- 134 participants
- Enrollment target
- 3
- Study locations
Study Summary
This trial is a single-arm, prospective, multi-center clinical trial designed to demonstrate that stereotactic adaptive radiotherapy using an ablatively dosed (50Gy,5fx) for treatment of borderline-resectable, locally-advanced , or medically inoperable pancreatic adenocarcinoma will translate into a decreased toxicity. The study will evaluate GI toxicity, overall survival, local control, quality of life, and workflow metrics.
Primary Outcome
The rate of acute Grade 3 or higher treatment related GI toxicities using CTCAE version 5.0 criteria
Conditions Studied
Interventions
- RADIATION Daily Adaptive External Beam Radiation Therapy
Study Locations (3)
Alabama
- University of Alabama at Birmingham - Birmingham
Missouri
- Washington University, St. Louis - St Louis
Ohio
- UH Cleveland Medical Center - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 134 participants |
| Start Date | 2023-05-14 |
| Est. Completion | 2030-03-15 |
| Phase | NA |
What NCT05764720 shows while recruiting
NCT05764720 is an interventional study that assigns participants to a tested intervention. The registered 134 participants enrollment target is mid-sized for trials with a published cap, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (66% lower).
The record links to 1 condition, with Pancreatic Cancer appearing as the primary indexed condition, and to 1 intervention - of which Daily Adaptive External Beam Radiation Therapy is the first listed.
NCT05764720 reports a single indexed study location in Alabama, Missouri, Ohio.
Frequently Asked Questions
What is clinical trial NCT05764720 about?
NCT05764720 is a clinical study titled "Stereotactic Adaptive Radiation Therapy of Borderline Resectable Pancreatic Cancer an Individualized Approach". This trial is a single-arm, prospective, multi-center clinical trial designed to demonstrate that stereotactic adaptive radiotherapy using an ablatively dosed (50Gy,5fx) for treatment of borderline-resectable, locally-advanced , or medically inoperable pancreatic adenocarcinoma will translate into a...
What is the current status of trial NCT05764720?
This trial is currently recruiting. It is a NA study. The enrollment target is 134 participants. The study started on 2023-05-14. Estimated completion is 2030-03-15.
What conditions does trial NCT05764720 study?
This clinical trial studies the following conditions: Pancreatic Cancer.
What interventions are being tested in trial NCT05764720?
The interventions under investigation include: Daily Adaptive External Beam Radiation Therapy (RADIATION).
Who is sponsoring clinical trial NCT05764720?
This trial is sponsored by Varian, a Siemens Healthineers Company, which has 16 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05764720 being conducted?
This trial has 3 study locations across Alabama, Missouri, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05764720's enrollment target sits among peer trials
134 85th of 278 higher than 193 of 278 other Pancreatic Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pancreatic Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Alpha Radiation Emitters Device for the Treatment of Pancreatic Cancer With Chemotherapy for the Treatment of Locally Advanced and Metastatic Pancreatic Cancer
RECRUITING · NA
-
A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue
RECRUITING · NA
-
EUS Examination Using EndoSound Vision System vs. Standard Echoendoscope
RECRUITING · NA
-
Computed Tomography in Diagnosing Patients With Pancreatic or Hepatobiliary Cancer
RECRUITING · NA
-
Support Through Remote Observation and Nutrition Guidance Program (STRONG-PCS)
RECRUITING · NA
-
GENOCARE: A Prospective, Randomized Clinical Trial of Genotype-Guided Dosing Versus Usual Care
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02469662 · 134 participants · NA
Clinical Outcomes Study of the Nexel Total Elbow
- NCT03110822 · 134 participants · Phase 1
A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients
- NCT05264857 · 134 participants · NA
Decision Aid and Thyroid Nodules Management
- NCT05819801 · 134 participants · NA
Effect of Fasting on Patient Outcomes After Wide-Awake, Local Anesthesia-only, No Tourniquet (WALANT) Procedures
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI